Why the study?
Does ivabradine improve automatic tachyarrhythmias in pediatric and congenital heart disease patients?
Does ivabradine improve automatic tachyarrhythmias in pediatric and congenital heart disease patients?
Answers are grounded in this paper and cite their sources.
Ivabradine is highlighted as a promising, hemodynamically neutral agent for managing automatic tachyarrhythmias in pediatric and congenital heart disease populations.
Key Teaching Points•Ivabradine is a novel heart rate–reducing agent that acts via selective inhibition of the pacemaker current.•Ivabradine demonstrates use dependence, resulting in a greater effect at higher heart rates.•Ivabradine has a hemodynamically neutral profile, in contrast to many alternative antiarrhythmic agents.•Ivabradine shows promise as an effective treatment for automatic tachyarrhythmias in pediatric and congenital heart disease patients. •Ivabradine is a novel heart rate–reducing agent that acts via selective inhibition of the pacemaker current.•Ivabradine demonstrates use dependence, resulting in a greater effect at higher heart rates.•Ivabradine has a hemodynamically neutral profile, in contrast to many alternative antiarrhythmic agents.•Ivabradine shows promise as an effective treatment for automatic tachyarrhythmias in pediatric and congenital heart disease patients.
No takes yet. Share an insight, caveat, or question.
Janson et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: